Since the initial association made by Trousseau in 1863, venous thromboembolism (VTE) has represented a major morbidity of the cancer experience. Estimates of the risk of VTE in cancer patients have ranged from 1% to as high as 40% depending on the particular patient experience examined. VTE in cancer patients also possesses a number of biological and clinical features distinct from VTE in the non-cancer population. The significance and uniqueness of this problem provides an important learning opportunity for both hematologists and oncologists.
This webinar was designed to provide a practical approach to the issue of thrombosis and cancer confronted by the busy practitioner on a daily basis. First, we explored risk assessment of VTE in cancer patients. Second, we reviewed a practical approach to VTE treatment in cancer patients, emphasizing its unique challenges. Finally, we addressed the specific issues of antithrombotic management in cancer patients with centrally-placed venous access. We provided adequate time for questions and answers at the end of the program.
Presentations and Speakers
Alok A. Khorana, MD, FACP
James P. Wilmot Cancer Center
Dr. Khorana focused on understanding risk factors and biomarkers for VTE in patients with cancer, and conducting risk assessment using a risk score. The emphasis was on recent data, updates and controversies regarding selecting the appropriate patients for thromboprophylaxis of cancer-associated VTE.
Agnes Y. Lee, MD, MSc, FRCPC
Diamond Health Care Centre
Dr. Lee reviewed the current treatment options for treating cancer patients with venous thromboembolism. The evidence, advantages and limitations, and practical insights of various anticoagulants were shared.
Elie Akl, MD
University of Buffalo
Dr. Akl discussed thromboprophylaxis in cancer patients with central venous catheters, including treatment of VTE in cancer patients with central venous catheters.
Vince Picozzi, MD
Virginia Mason Medical Center
back to top